Market Overview The cardiometabolic disease market is experiencing GLP-1 and SGLT2 inhibitor emphasis where multi-organ benefits, weight reduction, and cardiovascular protection drive adoption. The cardiometabolic disease market is projected to exceed USD 186.4 billion through 2030, with agent emphasis driven by multi-benefit efficacy, cardiovascular protection, and metabolic improvement. Novel...